This Dermatitis market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The dermatitis market size has grown strongly in recent years. It will grow from $6.77 billion in 2024 to $7.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increased prevalence, diagnostic advancements, treatment options, regulatory approvals.
The dermatitis market size is expected to see steady growth in the next few years. It will grow to $8.66 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to growing patient awareness, environmental factors. Major trends in the forecast period include research and development, telemedicine and digital health, biologics and targeted therapies, personalized medicine.
The growth of the dermatitis market is primarily attributed to the increasing global prevalence of the disease. The prevalence of dermatitis is estimated to be around 15-20% in children and 1-3% in adults. The rising incidence of food allergies is contributing to the prevalence of dermatitis, leading to a higher demand for medications to treat this condition. For instance, in October 2022, the Global Atopic Dermatitis Atlas (GADA), published by the International Eczema Council (IEC), reported approximately 223 million individuals affected by atopic dermatitis in 2022, with around 43 million in the age group of 1 to 4 years.
The rise in the global geriatric population is expected to drive the growth of the dermatitis market. Certain types of dermatitis, such as seborrheic and contact dermatitis, are more common in the elderly due to age-related changes in the skin, making them more susceptible to skin irritants and allergens. This creates an opportunity for the dermatitis market to develop specialized solutions to address the dermatological concerns of the aging population. For example, according to the World Health Organization in October 2022, the global population of individuals aged 60 years and older is projected to increase to 1.4 billion by 2022, compared to 1 billion in 2020. By 2030, one out of every six people in the world will be aged 60 years or older.
The dermatitis market has seen a trend of increasing mergers and acquisitions (M&As), aimed at business expansion and increased market visibility. Vendors in the industry are focusing on collaborations and partnerships to enhance their portfolios and market presence. M&As are strategic moves to reduce competition and increase business scalability. For instance, in March 2022, Pfizer Inc. acquired Arena Pharmaceuticals, Inc., a clinical-stage company developing treatments for dermatology diseases, including atopic dermatitis (AD). This acquisition strengthens Pfizer's portfolio of therapeutic candidates in fields like gastroenterology, dermatology, and cardiology.
Major companies in the dermatitis market are introducing innovative, clean-label, steroid-free products like ARCTIVA to gain a competitive edge and enhance their product offerings. ARCTIVA is a range of steroid-free skincare products designed to treat skin conditions such as eczema and psoriasis, featuring advanced Hydrosurf Glycolipid Technology. In April 2023, Arctiva Wellness, LLC introduced ARCTIVA, which combines scientific research with natural, cruelty-free ingredients and clinically validated, FDA-approved active components to deliver proven results. It is the exclusive product line featuring the revolutionary Hydrosurf Glycolipid Technology, originally discovered in Antarctica.
Major companies operating in the dermatitis market include LEO Pharma AS, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer AG, Encore Dermatology Inc., Meda Pharmaceuticals Inc., Allergan PLC, Bristol-Myers Squibb Co., Anacor Pharmaceutical Inc., Astellas Pharma Inc., Mylan N.V., Valeant Pharmaceutical Inc., Galderma SA, Dow Inc., Connetics Corporation, Fujisawa Pharmaceutical Company Ltd., AbbVie Inc., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, Medimmune Inc., Bausch Health Co. Inc., Nestlé Skin Health India Pvt. Ltd., Aqua Pharmaceuticals Pvt. Ltd., C.H. Boehringer Sohn AG & Co. KG, Biofrontera AG, Zydus Lifesciences Limited.
Dermatitis refers to treatments designed to alleviate skin inflammation, typically characterized by itchy rashes on the swollen and reddened outer layer of the skin. This is a broad term that encompasses various common skin irritations.
The primary categories of drugs used to manage dermatitis include corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates, and synthetic versions of these hormones are also used. These drugs can be administered through different routes, such as topical (applied to the skin), oral (taken by mouth), and injectable (administered by injection), and they find applications in the treatment of conditions like cancer, blood disorders, chronic diseases, and infectious diseases. Dermatitis treatments are available through various channels, including hospitals, retail pharmacies, drug stores, as well as online or mail-order pharmacies.
The dermatitis market research report is one of a series of new reports that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
North America was the largest region in the dermatitis market in 2024. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The dermatitis market size has grown strongly in recent years. It will grow from $6.77 billion in 2024 to $7.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increased prevalence, diagnostic advancements, treatment options, regulatory approvals.
The dermatitis market size is expected to see steady growth in the next few years. It will grow to $8.66 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to growing patient awareness, environmental factors. Major trends in the forecast period include research and development, telemedicine and digital health, biologics and targeted therapies, personalized medicine.
The growth of the dermatitis market is primarily attributed to the increasing global prevalence of the disease. The prevalence of dermatitis is estimated to be around 15-20% in children and 1-3% in adults. The rising incidence of food allergies is contributing to the prevalence of dermatitis, leading to a higher demand for medications to treat this condition. For instance, in October 2022, the Global Atopic Dermatitis Atlas (GADA), published by the International Eczema Council (IEC), reported approximately 223 million individuals affected by atopic dermatitis in 2022, with around 43 million in the age group of 1 to 4 years.
The rise in the global geriatric population is expected to drive the growth of the dermatitis market. Certain types of dermatitis, such as seborrheic and contact dermatitis, are more common in the elderly due to age-related changes in the skin, making them more susceptible to skin irritants and allergens. This creates an opportunity for the dermatitis market to develop specialized solutions to address the dermatological concerns of the aging population. For example, according to the World Health Organization in October 2022, the global population of individuals aged 60 years and older is projected to increase to 1.4 billion by 2022, compared to 1 billion in 2020. By 2030, one out of every six people in the world will be aged 60 years or older.
The dermatitis market has seen a trend of increasing mergers and acquisitions (M&As), aimed at business expansion and increased market visibility. Vendors in the industry are focusing on collaborations and partnerships to enhance their portfolios and market presence. M&As are strategic moves to reduce competition and increase business scalability. For instance, in March 2022, Pfizer Inc. acquired Arena Pharmaceuticals, Inc., a clinical-stage company developing treatments for dermatology diseases, including atopic dermatitis (AD). This acquisition strengthens Pfizer's portfolio of therapeutic candidates in fields like gastroenterology, dermatology, and cardiology.
Major companies in the dermatitis market are introducing innovative, clean-label, steroid-free products like ARCTIVA to gain a competitive edge and enhance their product offerings. ARCTIVA is a range of steroid-free skincare products designed to treat skin conditions such as eczema and psoriasis, featuring advanced Hydrosurf Glycolipid Technology. In April 2023, Arctiva Wellness, LLC introduced ARCTIVA, which combines scientific research with natural, cruelty-free ingredients and clinically validated, FDA-approved active components to deliver proven results. It is the exclusive product line featuring the revolutionary Hydrosurf Glycolipid Technology, originally discovered in Antarctica.
Major companies operating in the dermatitis market include LEO Pharma AS, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer AG, Encore Dermatology Inc., Meda Pharmaceuticals Inc., Allergan PLC, Bristol-Myers Squibb Co., Anacor Pharmaceutical Inc., Astellas Pharma Inc., Mylan N.V., Valeant Pharmaceutical Inc., Galderma SA, Dow Inc., Connetics Corporation, Fujisawa Pharmaceutical Company Ltd., AbbVie Inc., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, Medimmune Inc., Bausch Health Co. Inc., Nestlé Skin Health India Pvt. Ltd., Aqua Pharmaceuticals Pvt. Ltd., C.H. Boehringer Sohn AG & Co. KG, Biofrontera AG, Zydus Lifesciences Limited.
Dermatitis refers to treatments designed to alleviate skin inflammation, typically characterized by itchy rashes on the swollen and reddened outer layer of the skin. This is a broad term that encompasses various common skin irritations.
The primary categories of drugs used to manage dermatitis include corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates, and synthetic versions of these hormones are also used. These drugs can be administered through different routes, such as topical (applied to the skin), oral (taken by mouth), and injectable (administered by injection), and they find applications in the treatment of conditions like cancer, blood disorders, chronic diseases, and infectious diseases. Dermatitis treatments are available through various channels, including hospitals, retail pharmacies, drug stores, as well as online or mail-order pharmacies.
The dermatitis market research report is one of a series of new reports that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
North America was the largest region in the dermatitis market in 2024. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Dermatitis Market Characteristics3. Dermatitis Market Trends and Strategies4. Dermatitis Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Dermatitis Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Dermatitis Market34. Recent Developments in the Dermatitis Market
5. Global Dermatitis Growth Analysis and Strategic Analysis Framework
6. Dermatitis Market Segmentation
7. Dermatitis Market Regional and Country Analysis
8. Asia-Pacific Dermatitis Market
9. China Dermatitis Market
10. India Dermatitis Market
11. Japan Dermatitis Market
12. Australia Dermatitis Market
13. Indonesia Dermatitis Market
14. South Korea Dermatitis Market
15. Western Europe Dermatitis Market
16. UK Dermatitis Market
17. Germany Dermatitis Market
18. France Dermatitis Market
19. Italy Dermatitis Market
20. Spain Dermatitis Market
21. Eastern Europe Dermatitis Market
22. Russia Dermatitis Market
23. North America Dermatitis Market
24. USA Dermatitis Market
25. Canada Dermatitis Market
26. South America Dermatitis Market
27. Brazil Dermatitis Market
28. Middle East Dermatitis Market
29. Africa Dermatitis Market
30. Dermatitis Market Competitive Landscape and Company Profiles
31. Dermatitis Market Other Major and Innovative Companies
35. Dermatitis Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Dermatitis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dermatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatitis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Corticosteroids; Emollients or Moisturizers; Antihistamines; Calcineurin Inhibitors; Antibiotics; Immunomodulators; Interleukin Inhibitors2) By Distribution Channel: Hospital; Retail Pharmacies; Drug Stores; Online or Mail Pharmacies
3) By Application: Cancer; Blood Disorders; Chronic Diseases; Infectious Diseases
Subsegments:
1) By Corticosteroids: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids2) By Emollients or Moisturizers: Creams; Ointments; Lotions; Gels; Other Emollients or Moisturizers
3) By Antihistamines: Oral Antihistamines; Topical Antihistamines; Injectable Antihistamines
4) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors (Tacrolimus, Pimecrolimus); Oral Calcineurin Inhibitors
5) By Antibiotics: Topical Antibiotics; Oral Antibiotics; Systemic Antibiotics
6) By Immunomodulators: Topical Immunomodulators; Oral Immunomodulators
7) By Interleukin Inhibitors: IL-4 Inhibitors; IL-13 Inhibitors; IL-31 Inhibitors; Other Interleukin Inhibitors
Key Companies Mentioned: LEO Pharma aS; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi S.a.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Dermatitis market report include:- LEO Pharma AS
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Bayer AG
- Encore Dermatology Inc.
- Meda Pharmaceuticals Inc.
- Allergan Plc
- Bristol-Myers Squibb Co.
- Anacor Pharmaceutical Inc.
- Astellas Pharma Inc.
- Mylan N.V.
- Valeant Pharmaceutical Inc.
- Galderma SA
- Dow Inc.
- Connetics Corporation
- Fujisawa Pharmaceutical Company Ltd.
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Valeant Pharmaceuticals International Inc.,
- GlaxoSmithKline plc
- Medimmune Inc.
- Bausch Health Co. Inc.
- Nestlé Skin Health India Pvt. Ltd.
- Aqua Pharmaceuticals Pvt. Ltd.
- C.H. Boehringer Sohn AG & Co. KG
- Biofrontera AG
- Zydus Lifesciences Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 7.13 Billion |
| Forecasted Market Value ( USD | $ 8.66 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
